A personalised approach to treating patients with haematological malignancies

Chair: Mhairi Copland, University of Glasgow, UK
Speaker: Anna Schuh, University of Oxford, UK
Speaker: Susanne Saussele, University of Mannheim, Germany
Speaker: Paresh Vyas, University of Oxford, UK


Room: Lomond Auditorium

This session will explore how therapies are becoming increasingly targeted and individualised in the management of haematological cancers. Firstly, the session will consider how genomics in chronic lymphocytic leukaemia is guiding first line treatment and the use of targeted therapies. Next, the use of next generation sequencing to molecularly categorise patients with acute myeloid leukaemia will be discussed, together with how this is influencing delivery of standard and novel chemotherapeutic agents. Finally, we will review how targeted therapy in chronic myeloid leukaemia with tyrosine kinase inhibitors is leading to successful discontinuation of therapy in a substantial number of patients. Participants will gain an improved understanding of how molecular genomic studies are influencing therapy in haematological malignancies.